Most men in their thirties and forties have had their LDL checked. Most have not had their ApoB checked. That is a problem, because the marker that more directly predicts a future cardiovascular event is the one most standard panels still skip.
This is not a fringe opinion. It is the consensus from the lipidology and cardiology societies, repeated in guideline updates over the past several years. The ordering pattern in primary care has just been slow to follow.
What is ApoB?
Apolipoprotein B (ApoB) is a structural protein on the surface of every atherogenic lipoprotein particle in your bloodstream. That includes LDL, VLDL, IDL, and Lp(a). Each of those particles carries exactly one ApoB molecule. Count the ApoB, and you have counted the particles.
That is the leverage. LDL cholesterol is a concentration measurement, the amount of cholesterol carried inside the particles. ApoB is the particle count itself. Cardiovascular events are driven by particles entering the arterial wall, not by the cholesterol payload of any single particle.
How is ApoB different from LDL?
LDL cholesterol on a standard panel is usually calculated, not measured, using the Friedewald or Martin-Hopkins equations. It estimates the cholesterol content of LDL particles. It does not tell you how many particles you have.
Two men can have the same LDL of 100 mg/dL and very different ApoB. One has fewer large, cholesterol-rich particles. The other has many smaller, denser particles. The second man has higher cardiovascular risk despite an identical LDL number. ApoB sees the difference. LDL does not.
This discordance is common in men with metabolic dysfunction. Higher triglycerides, lower HDL, central adiposity. The exact phenotype where LDL most often underestimates true risk is the phenotype most relevant to the men we work with.
ApoB target ranges
- Under 60 mg/dL: Optimal for men with established cardiovascular disease, prior events, or strong family history. The "secondary prevention" range.
- Under 80 mg/dL: Ideal for men with elevated risk factors (insulin resistance, hypertension, family history of early MI, elevated Lp(a), diabetes).
- Under 90 mg/dL: A reasonable target for most healthy men over 35 with no major risk factors.
- Above 100 mg/dL: Elevated. Worth a clinical conversation regardless of LDL number.
- Above 130 mg/dL: High. The risk curve is steep above this line.
These ranges align with current lipidology society guidance. Your clinician may tighten them based on family history, Lp(a), or imaging.
Who should test ApoB?
Almost every adult man, at least once. The case for ordering it routinely is strongest if any of the following apply:
- Family history of early cardiovascular events (father before 55, mother before 65).
- LDL anywhere above 70 mg/dL.
- Triglycerides above 130 mg/dL.
- HDL below 40 mg/dL.
- Any metabolic dysfunction: rising fasting insulin, A1c above 5.6, central adiposity.
- Hypertension or pre-hypertension.
- Anyone on or considering a lipid-lowering therapy.
The test is inexpensive. It is on most major reference lab menus. It does not require fasting in most assays. There is very little reason not to know your number.
How does the test actually work
ApoB is a direct immunoassay. The lab uses an antibody to bind ApoB and measure the signal. The result is in mg/dL. It is more reproducible than LDL calculation, especially when triglycerides are elevated or after a non-fasting draw, because it does not depend on a formula.
For most men, a baseline ApoB plus a repeat in 12 to 16 weeks (after a lifestyle change or medication start) is enough to track the trend.
What moves ApoB
The same levers that move LDL move ApoB, with a few specifics:
- Saturated fat reduction: lowers ApoB in most men, though the effect size varies.
- Soluble fiber (oats, legumes, psyllium): modest but reliable ApoB reductions.
- Weight loss, especially loss of visceral fat: lowers ApoB and the small-dense particle fraction.
- Statins: lower ApoB significantly. The effect is usually deeper than the LDL number suggests.
- Ezetimibe: adds another 15% to 25% on top of a statin.
- PCSK9 inhibitors: drop ApoB profoundly. Reserved for higher-risk patients.
The lifestyle levers compound. A man who tightens his diet, drops 15 pounds of visceral fat, and adds resistance training will often see ApoB fall 20 to 40 mg/dL without any medication.
How ApoB fits into a full panel
ApoB is one number. It is not the only one. We run it alongside Lp(a), fasting insulin, hs-CRP, A1c, and the standard lipid panel. The combination tells a story that no single marker tells alone. We cover the full set in The panel a man should run after 35.
If you have never had your ApoB measured, that is the easiest thing to fix this quarter. Order the test. Read the number. Then decide what, if anything, to do about it. The Vane Baseline panel includes ApoB by default for exactly this reason.
Where this lands
ApoB is not a new marker. It has been in the literature for decades. What is new is that the consensus has finally caught up to the data, and the test is now ordered routinely by clinicians who follow the lipidology evidence.
For a man over 35 making any decision about cardiovascular risk (whether to start a statin, whether to push harder on diet, whether to add a GLP-1 for the metabolic signal), ApoB is the cleaner number to make that decision against. LDL is the rough draft. ApoB is the manuscript.
Run it once. The number will inform a decade of decisions.
